8-K: Genprex Announces New Research Agreement with University of Pittsburgh for GPX-002 Diabetes Gene Therapy

Genprex, Inc. has entered into a new Sponsored Research Agreement with the University of Pittsburgh to further study GPX-002, its gene therapy for Type 1 and Type 2 diabetes, following promising preclinical results.

Summary

• Genprex has entered into a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy for Type 1 diabetes (T1D) and Type 2 diabetes (T2D).
• The new SRA follows the completion of a previous two-year SRA between the parties.
• Preclinical data from an animal study of GPX-002 in T1D showed statistically significant decreases in insulin requirements, increases in c-peptide levels, and improvements in glucose tolerance compared to baseline.
• GPX-002 is designed to transform alpha cells into functional beta-like cells in T1D and rejuvenate exhausted beta cells in T2D.
• The therapy involves administering an adeno-associated virus vector containing the Pdx1 and MafA genes directly into the pancreatic duct, which can be done via a routine endoscopy procedure in humans.
• In vivo, preclinical studies showed that GPX-002 restored normal blood glucose levels for an extended period of time in T1D mouse models.

Sentiment

Score: 7

Explanation: The announcement is positive due to the new research agreement and promising preclinical data, but tempered by the standard cautionary language regarding forward-looking statements and financial risks.

Positives

• The new SRA with the University of Pittsburgh demonstrates continued commitment to developing GPX-002.
• Preclinical data shows promising results in animal models for both T1D and T2D.
• GPX-002 has the potential to address both T1D and T2D with the same construct.
• The administration method via endoscopy is a routine procedure in humans.

Risks

• The announcement contains cautionary language regarding forward-looking statements, highlighting the risks and uncertainties associated with clinical development, regulatory approvals, and commercialization.
• Genprex's ability to maintain compliance with Nasdaq listing requirements and secure sufficient capital is uncertain.
• The success of strategic partnerships with third-party vendors, suppliers, and manufacturers is crucial for scaling up production.
• The company's intellectual property and licenses are subject to risks.

Future Outlook

The company plans to advance the clinical development, manufacturing, and commercialization of its product candidates, including GPX-002, and conduct preclinical studies and potential future clinical trials.

Management Comments

• The Company believes these groundbreaking results support the hypothesis that this disruptive gene therapy approach developed by Pitt researchers may be a promising treatment for both T1D and T2D.

Industry Context

Gene therapy for diabetes is an emerging field, and Genprex's approach of targeting pancreatic cells directly could offer a novel treatment option compared to traditional insulin therapies.

Comparison to Industry Standards

• Other companies like Vertex Pharmaceuticals are also exploring cell therapies for Type 1 diabetes, but Genprex's gene therapy approach is distinct.
• The success of GPX-002 will be benchmarked against existing diabetes treatments and other emerging gene and cell therapies in terms of efficacy, safety, and durability of effect.

Stakeholder Impact

• Positive for shareholders due to the potential of GPX-002.
• Positive for patients with T1D and T2D if the therapy proves effective.
• Positive for the University of Pittsburgh through the sponsored research agreement.

Next Steps

• Genprex will conduct preclinical studies of GPX-002 for the treatment of T1D and T2D in animal models.
• The company plans to advance the clinical development, manufacturing, and commercialization of its product candidates.

Key Dates

Keywords

GPX-002, gene therapy, diabetes, Type 1 diabetes, Type 2 diabetes, Genprex, University of Pittsburgh, Sponsored Research Agreement, preclinical studies, insulin, c-peptide, glucose tolerance, pancreas, Pdx1, MafA